Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cytoplasmic or inner membrane (IM) of Gram-negative bacteria is a phospholipid bilayer essential for maintaining the cell's structural integrity and electrochemical gradient [1]. It is primarily composed of phosphatidylethanolamine (PE), phosphatidylglycerol (PG), and cardiolipin (CL), which facilitate vital processes such as ATP synthesis, protein secretion, and lipid biosynthesis [2]. Unlike the outer membrane, the IM lacks lipopolysaccharides but is the site of action for several classes of antibiotics that must first traverse the cell wall [3]. Drugs like polymyxins (e.g., Colistin) and various antimicrobial peptides (AMPs) target these lipids, particularly the anionic PG and CL, to cause membrane depolarization and pore formation [4]. This disruption leads to the leakage of essential ions and metabolites, ultimately resulting in rapid bacterial cell death [5]. Targeting the IM is a key strategy against multi-drug resistant (MDR) pathogens, though the similarity between certain bacterial and mammalian lipids can lead to host toxicity, such as nephrotoxicity [6]. Sources: [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262121/; [2] https://www.uniprot.org/locations/SL-0038; [3] https://pubmed.ncbi.nlm.nih.gov/27317921/; [4] https://pubchem.ncbi.nlm.nih.gov/compound/Colistin; [5] https://www.nature.com/articles/s41598-017-12703-6; [6] https://www.ncbi.nlm.nih.gov/books/NBK557777/.
Drugs targeting these lipids typically act by binding to anionic phospholipids (such as phosphatidylglycerol and cardiolipin), leading to membrane depolarization, pore formation, and physical disruption of the lipid bilayer, which results in the leakage of intracellular contents and rapid cell death.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial cytoplasmic membrane lipids.